1. |
- He, Xinkui, et al.
(author)
-
Spatial and spectral properties of the high-order harmonic emission in argon for seeding applications
- 2009
-
In: Physical Review A (Atomic, Molecular and Optical Physics). - 1050-2947. ; 79:6
-
Journal article (peer-reviewed)abstract
- We characterize and control the harmonic emission in the spectral and spatial domains in order to define in which conditions the harmonic radiation can be a high-quality seed for soft x-ray and x-ray free-electron lasers. The length of the gas cell, where harmonics are generated, was optimized and the energy per pulse was determined in absolute value with a calibrated x-ray photodiode. The beam spatial profile was measured and, in some conditions, a very collimated beam with a half-angle divergence below 1 mrad could be obtained. We also show that increasing the intensity of the fundamental laser field leads to a considerable broadening of the bandwidth of the harmonic radiation, allowing us to cover a large spectral range. This effect is due to fundamental reshaping leading to an efficient phase matching of both short- and long-trajectory contributions.
|
|
2. |
- Rakowski, Tomasz, et al.
(author)
-
Early abciximab administration before transfer for primary percutaneous coronary interventions for ST-elevation myocardial infarction reduces 1-year mortality in patients with high-risk profile. Results from EUROTRANSFER Registry
- 2009
-
In: AMERICAN HEART JOURNAL. - : Elsevier BV. - 0002-8703. ; 158:4, s. 569-575
-
Journal article (peer-reviewed)abstract
- Background There are conflicting data on the clinical benefit from early administration of abciximab from a large randomized trial and a registry. However, both sources suggest that a benefit may depend on the baseline risk profile of the patients. We evaluated the role of early abciximab administration in patients with ST-segment-elevation myocardial infarction (STEMI) referred for primary percutaneous coronary intervention stratified by the STEMI Thrombolysis In Myocardial Infarction (TIMI) risk score. Methods A total of 1,650 patients were enrolled into the EUROTRANSFER Registry. One thousand eighty-six patients received abciximab (66%). Abciximab was administered early in 727 patients (EA) and late in 359 patients (LA). We used the TIMI risk score for risk stratification. Patients with scores 3 constituted the high-risk group of 616 patients (56.7%), whereas 470 patients formed the low-risk cohort. Factoring in the timing of the abciximab administration resulted in 4 groups of patients who were compared for mortality at 1 year: EA/high-risk (n = 413); LA/high-risk (n = 203); EA/low-risk (n = 3 14); LA/low-risk (n = 156). Baseline difference was accounted for by means of propensity score. Results In high-risk patients, 1-year mortality was significantly lower with early abcximab compared to late administration (8.7% vs 15.8%; odds ratio 0.51, CI 0.31-0.85, P = .01). In multivariable Cox regression analysis, both early abciximab administration and patients risk profile (TIMI score :3) were identified as independent predictors of 1-year mortality. Conclusions Early abciximab administration before transfer for percutaneous coronary intervention in STEMI shows lower mortality at 1-year follow-up. This effect is confined to patients with higher risk profile as defined by TIMI risk score andgt;= 3.
|
|